Trials / Completed
CompletedNCT00606866
MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine maximum tumor shrinkage, time to progression, survival, drug concentration, and degree of skin toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | Placebo for four weeks |
| DRUG | Sorafenib | Sorafenib 200 mg twice daily |
| DRUG | Sorafenib | Sorafenib, 400 mg twice daily |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2007-01-01
- Completion
- 2008-06-01
- First posted
- 2008-02-05
- Last updated
- 2023-11-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00606866. Inclusion in this directory is not an endorsement.